ConvaTec, the wound dressings manufacturer, has bought Dutch rival Eurotec Beheer for €25m (£21.3m), in the company’s first acquisition since listing on the stock market in October.
Reading-based ConvaTec was valued at more than £4bn when it went public, making it the biggest flotation on the London stock market last year and the largest ever European healthcare listing.
A major reason behind the decision to go public was to raise the company’s profile to drive ambitious growth plans, which include expanding into new markets and launching more products.
EuroTec, which was founded in 1996, manufactures and distributes ostomy systems and accessories on the continent and is the only manufacturer of these products in the Netherlands.
Ostomy care is an area of medicine in which patients have pouches fitted to their abdomens to drain urine or stools, such as a colostomy bag.
Paul Moraviec, chief executive of ConvaTec, said the acquisition would strengthen the company’s ostomy business in France and the Benelux region, two areas he said were “important pillars of the growth strategy for our ostomy care franchise”. The acquisition also includes EuroTec’s production facilities in the Netherlands.
FTSE 100-listed ConvaTec also makes dressings to contain oozing wounds, endotracheal tubes, catheters, surgical suction devices and faecal incontinence equipment.
The company’s products help people with long-term illnesses and the market is growing, driven by increasing life expectancy and greater incidence of chronic health conditions.
ConvaTec was founded in 1978, has 9,000 employees and operates in more than 100 countries. In the UK, it employs 1,000 staff and carries out all of its R&D work in North Wales.
Avista and Nordic Capital bought ConvaTec from US pharmaceuticals giant Bristol-Myers Squibb in 2008 for $4.1bn (£3.18bn) and remain shareholders.
By Julia Bradshaw
Source: The Telegraph
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
